MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro
- 30 September 2010
- journal article
- Published by Elsevier in Clinical Immunology
- Vol. 136 (3), 338-347
- https://doi.org/10.1016/j.clim.2010.04.013
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanomaThe Journal of Experimental Medicine, 2010
- Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsThe Journal of Experimental Medicine, 2010
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenBlood, 2009
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefitProceedings of the National Academy of Sciences, 2008
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative RegimensJournal of Clinical Oncology, 2008
- Polyfunctional T cell responses are a hallmark of HIV‐2 infectionEuropean Journal of Immunology, 2008
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Simultaneous Generation of CD8+ and CD4+ Melanoma-Reactive T Cells by Retroviral-Mediated Transfer of a Single T-Cell ReceptorCancer Research, 2005
- Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR αβ gene transfer requires CD8αGene Therapy, 2004
- Helping the CD8+ T-cell responseNature Reviews Immunology, 2004